ReviewCurrent pharmaceutical design2025
A Spotlight on PLGA-based Nanoparticles: Pioneering a New Era in the Therapeutics of Cardiovascular Disorders.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancements in nanomaterials for the treatment and management of vascular surgeries: from drug delivery to biomedical implants.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disorders (CVDs) are the primary cause of mortality globally, and the community is significantly affected when young people suffer from CVDs. Coronary artery disease, myocardial infarction, fibrosis, atherosclerosis, pulmonary arterial hypertension, thrombosis, and ischemic diseases are different types of CVDs, which encompass a wide range of conditions that interfere with the functioning of the cardiovascular system. The relevance of nanotechnology in the treatment of CVDs has emerged progressively in previous decades.
objectiveThis review offers concise insights into the physiochemical characteristics of poly (lactic-coglycolic acid) (PLGA) imperative for drug delivery. This article highlights the application of PLGA-NPs in myocardial ischemia, atherosclerosis, myocardial infarction, pulmonary artery hypertension, valvular heart disease, tumour thrombus, cardiac myocyte, restenosis, cardiovascular theranostics, vascular disorders, and angiogenesis. Further, this review gives updates about published patents pertaining to the current state-of-art about PLGA-NPs in CVDs.
methodsAn extensive review was undertaken employing the Google Scholar, PubMed, and ScienceDirect databases using scientific papers published in peer-reviewed journals from 2000 to 2024.
resultsOwing to their minuscule size and increased surface area accessible for surface functionalization, the PLGA-NPs offer a cutting-edge technology to provide an efficient platform for controlled and targeted drug delivery, therefore, imparting tremendous relevance in reducing the occurrence of CVDs.
conclusionThis has been concluded that PLGA is the highly effective biodegradable copolymer, also known as "Smart polymers," because of their biodegradability, biocompatibility, controlled drug release profile, and potential for surface modification with targeting molecules.
Indexed as
Identifiers
40325566What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.